Sweden Archives

News and Trends 18 May 2015

Allergist Circassia grabs a couple of Asthma-Specialist companies

The allergy specialist Circassia will acquire two asthma-expert companies: Aerocrine and Prosonix. The British company, which performed the biggest of the fifteen European biotech IPOs in 2014, intends to become a self-sustaining biopharma by focusing on allergies and asthma. The purchases will optimize the launch of CAT-Spire, which represents Circassia’s first drug of a new […]

May 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 4 May 2015

Karolinska Development took a Step Back in its Biotech portfolio

The finances of Karolinska Development remain in a dangerous downward spiral as the company dropped to €136.9M (SEK 1,277 million), an unsatisfactory record for the company, the lowest valuation since 2011. For this purpose, the company decided to totally abandon investing in Pergamum, Umecrine and NeoDynamics AB, three biotech companies. Karolinska’s reaction is well-defined: the […]

May 4, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Apr 2015

Wilson Therapeutics on its way to cure Wilson disease

Wilson Therapeutics has closed a €37.4M Series B financing to advance its late-stage development program for Wilson’s disease. The company will present its ongoing Phase II trial of WTX101-201, the company’s treatment for this disease, at the upcoming 50th International Liver Congress 2015. Approximately 1 in 15000 people worldwide have Wilson Disease, a rare genetic disorder that prevents the […]

April 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 30 Jan 2015

The Human Protein Atlas: exploring human geography

Some 20 years ago, before the genomic era, isolating a protein and identifying the tissue where it was present was enough to get a PhD. Swedish researchers just did it for all the proteins in the human body: the equivalent of 20,000 thesis from the pregenomic age, at a stroke. Thanks to the ‘omics’, the […]

January 30, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 15 Aug 2014

Active Biotech and Teva together in a Phase II clinical trial against Huntington’s disease

Active Biotech announced today that its partner Teva Pharmaceutical will initiate a phase II clinical trial to evaluate the efficacy and safety of oral laquinimod for the treatment of Huntington’s disease. Laquinimod is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed primarily for the treatment of relapsing-remitting multiple sclerosis […]

August 15, 2014 - 1 minutemin - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us